Quotient Sciences Quotient Sciences

X

Find the latest Drugs in Development and Pipeline Prospector News of Sensorion.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Sensorion
France Flag
Country
Country
France
Address
Address
375, rue du Professeur Joseph Blayac 34080 MONTPELLIER
Telephone
Telephone
+33 (0)4 67 20 77 30

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The financing aims to fund the clinical development of SENS-501 (OTOF-GT) small molecule programs for the treatment and prevention of hearing loss disorders.


Lead Product(s): OTOF-GT

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501

Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Redmile Group

Deal Size: $16.2 million Upfront Cash: Undisclosed

Deal Type: Financing April 08, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 11, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through financing, Sensorion will prioritize the development of SENS-501 ( OTOF-GT), which aims to restore hearing in individuals with Otoferlin deficiency, a prevalent form of congenital deafness.


Lead Product(s): OTOF-GT

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501

Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Redmile Group

Deal Size: $54.4 million Upfront Cash: Undisclosed

Deal Type: Financing February 09, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (arazasetron) is an orally available 5-HT3 receptor antagonist, small molecule drug. It is being evaluated in phase 2 clinical trials for the treatment of hearing loss.


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 01, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-501 (OTOF-GT) dual vector AAV gene therapy development program aims to restore hearing in patients with mutations in the gene coding for otoferlin protein who suffer from severe to profound sensorineural prelingual non-syndromic hearing loss.


Lead Product(s): OTOF-GT

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501

Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 19, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Sensorion and Institut Pasteur will focus on the development of two gene therapy programs, including SENS-501 (OTOF-GT), which targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT, which targets hearing loss related to mutations in GJB2 gene.


Lead Product(s): SENS-501

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Institut Pasteur

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership January 05, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-401 (Arazasetron) is a 5-HT3 receptor antagonist and calcineurin inhibitor, orally available small molecule, which is under phase 2 clinical development for the treatment of Cisplatin-Induced Ototoxicity (CIO).


Lead Product(s): R-Azasetron Besylate

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-401

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.


Lead Product(s): SENS-501

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT

Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 19, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

OTOF-GT is a dual AAV vector gene therapy development program aims to restore hearing in patients with mutations in OTOF who suffer from severe to profound sensorineural prelingual non syndromic hearing loss.


Lead Product(s): OTOF-GT

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: OTOF-GT

Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

SENS-501 is an adeno-associated vector-based gene therapy for the autosomal recessive non-syndromic Deafness 9. It is being investigated in preclinical stage for DFNB9.


Lead Product(s): SENS-501

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SENS-501

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 02, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY